Impact of real-time, dose-escalated permanent seed implant brachytherapy in intermediate-risk prostate cancer

Purpose: To retrospectively evaluate biochemical control and toxicity in patients who underwent 1251 seed brachytherapy (BT) for intermediate-risk prostate cancer (PCa). Materials and Methods: Between January 2004-December 2014, 395 patients with intermediate-risk PCa underwent 1251 BT. Of these, 117 underwent preoperative planning (PP; 145 Gy) and 278 real-time intraoperative preplanning (IoP ; 160 Gy). All patients were followed for >= 6 months (> 5 years in 48% of patients and > 7 years in 13%). Median follow-up was 59 months. Results: Biochemical relapse-free survival (BRFS) rates at 5 and 8 years were, respectively, 91.7% and 82.1%. By treatment group, the corresponding BRFS rates were 93.5% and 90% for IoP and 89% and 76.8% for PP. The maximum dose to the urethra remained unchanged (217 Gy) despite the dose escalation (from 145 to 160 Gy), without any significant increase in treatment-related toxicity (p = 0.13). Overall toxicity outcomes in the series were excellent, with only 3 cases (0.76%) of grade 3 genitourinary toxicity. Conclusion: The real-time intraoperative planning technique at 160 Gy yields better biochemical controls than the preoperative planning technique at 145 Gy. Dose escalation did not increase urinary toxicity. The excellent results obtained with the IoP BT technique support its use as the first treatment option in this patient population. (C) 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.